Coming back to: Official shortage notices and what they authorise

Resuming after a gap: after a gap of days or a few weeks, most people resume at the dose they were on when they stopped. Gaps of months might require retitration discussion with a clinician.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is prudent if you can.

Worth separating two things that post #14 runs together.

Communication from suppliers: a supplier having supply problems usually communicates them. If a supplier goes silent, that is itself information.

Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage. That permission is jurisdiction-specific and time-limited (usually for the duration of the shortage).

Allocation and rationing: during severe shortages, suppliers might ration allocation to prescribers. Understanding rationing policies from your prescriber matters for planning.

Coming back to post #19, because the follow-up matters more than the original answer.

Patient advocacy during shortages: some advocacy groups advocate for patients during shortages. Knowing who they are and following their communication is useful.

Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.

Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.

post #23 answers the question as asked. The question underneath it is different.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are different decisions.

Worth separating two things that post #23 runs together.

Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the regulatory website for shortages gives you advance notice.

post #27 is right about the mechanism and I think understates the practical bit.

Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.

Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.

Picking up post #27: that is the part I would want checked first.

Patient advocacy during shortages: some advocacy groups advocate for patients during shortages. Knowing who they are and following their communication is useful.